Toronto - A group of Canadian physicians who use Artecoll, an injectable currently awaiting FDA approval, is calling for the development of formal clinical guidelines and further research to help avoid adverse patient reactions.
Derm In The News: February 18-24
ReV Up Your Vitiligo Treatment Strategies
La Roche-Posay Unveils New Molecule in Mela B3 Serum to Target Discoloration
The Cutaneous Connection: Splish, Splash, AD Management Starts in the Bath
Atopic Dermatitis Itch May Be Caused by Microbes, Not Inflammation
Cysteamine Isobionic-Amide Complex Demonstrates On Par Efficacy, Onset of Action in Melasma as Kligman's Formula
2 Commerce Drive Cranbury, NJ 08512